Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Nasopharyngeal Cancer: early-phase trial registry

2 of 5 indexed Nasopharyngeal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Nasopharyngeal Cancer: 5 US clinical trials tracked, 2 recruiting.

Nasopharyngeal Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Poseida Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition nasopharyngeal-cancer

OPEN 2 | RECR 40% | LATE 0 | EARLY 3 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Nasopharyngeal Cancer (this)40%
Open-enrollment share among volume-matched conditions near Nasopharyngeal Cancer

Nasopharyngeal Cancer lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nasopharyngeal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nasopharyngeal Cancer is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Nasopharyngeal Cancer research.

    Poseida Therapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Nasopharyngeal Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 66 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Nasopharyngeal Cancer research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Nasopharyngeal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PET/CT scans Diagnostic test
1 trials
P-MUC1C-ALLO1 CAR-T cells Biological
1 trials
VK-2019 Drug
1 trials
BL-B01D1 Drug
1 trials
Radiographic Imaging Procedure
1 trials
Intensity-Modulated Radiation Therapy (IMRT) Radiation
1 trials
Rimiducid Drug
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Nasopharyngeal Cancer trials. A trial with sites in several states counts in each.

California 4 trials
New York 3 trials
Massachusetts 2 trials
Iowa 2 trials
Colorado 2 trials
Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nasopharyngeal Cancer page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nasopharyngeal Cancer condition card totals 5 registered trials; most-linked intervention PET/CT scans; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.